Top

International Urogynecology Journal

Published in:

01-06-2009 | Original Article

Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin

Authors: Peter K. Sand, William D. Steers, Roger Dmochowski, Masakazu Andoh, Sergio Forero-Schwanhaeuser

Published in: International Urogynecology Journal | Issue 6/2009

Abstract

Introduction and hypothesis

In overactive bladder (OAB), subjects' most bothersome symptom (MBS) may influence treatment-related outcomes. We evaluated effects of solifenacin on patient-reported outcomes (PROs) in subjects stratified by their MBS at baseline.

Methods

In a 12-week, open-label study, the effects of solifenacin on PROs were assessed using visual analog scales (VAS), the OAB questionnaire (OAB-q), and the patient perception of bladder condition (PPBC). Statistics were descriptive.

Results

Subjects' baseline MBS were frequency (27%), urge urinary incontinence (UUI; 26%), urgency (23%), and nocturia (15%); VAS scores were worse for MBS. By study end, participants' MBS showed the largest solifenacin-related VAS improvements. The UUI subgroup showed the largest VAS, OAB-q, and PPBC improvements.

Conclusions

Solifenacin improved overall and symptom-specific bother, HRQL, and perception of their bladder condition in MBS subgroups, with larger improvements in subjects' MBS. Those with UUI as MBS showed greater improvement in most outcomes.

Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef

Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314 discussion 1314–1305PubMedCrossRef

Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Sand PK (2004) Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract 16:8–11PubMed

Staskin DR, MacDiarmid SA (2006) Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119:9–15PubMedCrossRef

Epstein BJ, Gums JG, Molina E (2006) Newer agents for the management of overactive bladder. Am Fam Physician 74:2061–2068PubMed

Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59:931–937PubMedCrossRef

Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMed

Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086PubMedCrossRef

10.

Abrams P, Artibani W, Gajewski JB, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68:17–28PubMedCrossRef

11.

Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60:745–751PubMedCrossRef

12.

Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V (2006) Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 60:752–758PubMedCrossRef

13.

Coyne KS, Elinoff V, Gordon DA et al (2008) Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 62:925–931PubMedCrossRef

14.

Garely AD, Kaufman JM, Sand PK, Smith N, Masakazu A (2006) Symptom bother and health-related quality of life outcomes following Solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT). Clin Ther 28:1935–1946PubMedCrossRef

15.

Leung HY, Yip SK, Cheon C et al (2002) A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 90:375–380PubMedCrossRef

16.

Davila GW, Daugherty CA, Sanders SW (2001) A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166:140–145PubMedCrossRef

17.

Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW (2003) Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237–242PubMedCrossRef

18.

Stach-Lempinen B, Kujansuu E, Laippala P, Metsänoja R (2001) Visual analogue scale, urinary incontinence severity score and 15 D–psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol 35:476–483PubMedCrossRef

19.

Lukacz ES, Lawrence JM, Burchette RJ, Luber KM, Nager CW, Buckwalter JG (2004) The use of Visual Analog Scale in urogynecologic research: a psychometric evaluation. Am J Obstet Gynecol 191:165–170PubMedCrossRef

20.

Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef

21.

Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849–855PubMedCrossRef

22.

Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V (2006) Determining the importance of change in the overactive bladder questionnaire, discussion 632. J Urol 176:627–632 discussion 632PubMedCrossRef

23.

Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS (2005) Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 24:215–225PubMedCrossRef

24.

Garely AD, Lucente V, Vapnek J, Smith N (2007) Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother 41:391–398PubMedCrossRef

25.

Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924PubMedCrossRef

26.

Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93:71–77PubMedCrossRef

27.

Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310PubMedCrossRef

28.

Chapple CR, Cardozo L, Steers WD, Govier FE (2006) Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 60:959–966PubMedCrossRef

29.

Institute of Medicine (2001) Crossing the quality chasm: a new health system for the 21st century. National Academy of Sciences, Washington DC

Title: Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin
Authors: Peter K. Sand
William D. Steers
Roger Dmochowski
Masakazu Andoh
Sergio Forero-Schwanhaeuser
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 6/2009
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-009-0840-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

Significant improvement in the quality of life in women treated with a novel disposable intravaginal device for stress urinary incontinence

Surgical footprints, then and now: response to comment by Dietz

Clinical-decision taking in primary pelvic organ prolapse; the effects of diagnostic tests on treatment selection in comparison with a consensus meeting

Validation of a German version of the P-QOL Questionnaire

Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital

Urogynecology fellowship training program directory